期刊文献+

慢性阻塞性肺疾病患者血浆内脏脂肪因子水平变化及其与营养状况的关系 被引量:7

Relationship between Changes in Plasma Visfatin Levels and Nutritional Status in Chronic Obstructive Pulmonary Disease Patients
下载PDF
导出
摘要 目的探讨血浆内脏脂肪因子(visfatin)水平变化在稳定期COPD伴营养不良患者中的意义。方法测定40例稳定期COPD患者(分为COPD伴营养不良组20例,COPD不伴组20例)及20例健康体检者的血浆visfatin、肿瘤坏死因子(TNF-α)、C反应蛋白(CRP)、瘦素(LEP)及与营养状况相关的人体重指数(BMI)。Visfatin、TNF-α等指标采用酶联免疫吸附法测定。分析visfatin与TNF-α、CRP、BMI等指标之间的相关性。结果①COPD伴营养不良组血浆visfatin浓度为(19.56±4.69)ng/ml明显高于COPD不伴营养不良组(P<0.01);②40例稳定期COPD患者血浆visfatin水平与TNF-α、CRP、LEP值呈负相关(r值分别为-0.397、-0.459,P<0.05或P<0.01),与BMI水平存在正相关(r=0.407,P<0.01)。结论血浆visfatin水平可以反映稳定期COPD患者的营养状况,其水平的变化可能在稳定期COPD患者伴发营养不良的过程中起到重要作用,但其具体机制还需进一步研究。 Objective To explore the changes and implications of plasma visfatin levels in malnourished patients with chronic ob- structive pulmonary disease(COPD) at stable stage. Methods The plasma cytokine levels (Visfatin, LEP,TNF -α and CRP) and hu- man nutrition index (BMI) of 40 patients from COPD at stable stage and 20 healthy people were assayed, and the differences and correla- tion between the three groups were cempared. The levels of cytokine was determined by ELISA. Results (1)The plasma visfatin levels of malnoarished patients were higher than those of no malnourished patients with COPD at stable stage ( P 〈 0.01 ). (2)The plasma visfatin levels in 40 patients with COPD at stable stage were negative correlative to the plasma CRP, LEP,TNF- α (r = -0. 477, -0. 407, - 0. 365, P 〈 0.05 or P 〈 0.01 ). Conclusion Plasma visfatin levels can reflect the nutrition status of patients with chronic obstructive pulmonary disease at stable stage. Levels change of visfatin may play the key role during the process of malnourished patients with chronic obstructive pulmonary disease at stable stage.
出处 《医学研究杂志》 2013年第4期60-63,共4页 Journal of Medical Research
基金 浙江省中医药科学研究基金资助项目(2012ZA009)
关键词 COPD 稳定期 营养状况 内脏脂肪因子 COPD Stable phase Nutritional status Visfatin
  • 相关文献

参考文献15

  • 1Roig M, Eng JJ, Road JD, et al. Falls in patients with chronic obstruc- tive pulmonary disease : a call for further research [ J ]. Respiratory Medicine Medicine ,2009,103 ( 9 ) : 1257 - 1269.
  • 2陈文宇,钦光跃.慢性阻塞性肺疾病伴发营养不良的机制及其干预研究进展[J].国际呼吸杂志,2011,31(23):1820-1824. 被引量:13
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8234
  • 4Liu XJ,Ji YL,Chen J,et al. Circulating visfatin in chronic obstructive pulmonary disease [ J ]. Nutrition,2009,25 (4) : 373 - 378.
  • 5Liu ZB, Song NN, Geng WY,et al. Orexin - A and respiration in a rat model of smoke - induced chronic obstructive pulmonary disease [ J ].Clinical and Experimental Pharmacology & Physiology ,2010,37 ( 10 ) : 963 - 968.
  • 6Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin : a protein secre- ted by visceral fat that mimics the effects of insulin [ J ]. Science, 2005,307 (5708) :426 - 430.
  • 7Sethi JK, Vidal Puig A. Visfatin:the missing link between intra - ab- dominal obesity and diabetes [ J ]. Trends Mol Med,2005, 11 ( 8 ) :344 - 347.
  • 8吴静,王宏伟,温宇.新型脂肪因子visfatin的生物学意义[J].生理科学进展,2006,37(4):353-355. 被引量:4
  • 9Kralisch S,Klein J,Lossner U,et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3 - L1 adipocytes[ J ]. J Endecrinol,2005, 185(3):R1-R8.
  • 10Kralisch S, Klein J, Lossner U,et al. Interleukin -6 is a negative regu- lator of visfatin gene expression in 3T3 - L1 adipocytes [ J]. Am J Physiol Endecrinol Metab,2005,289 (4) : E586 - E590.

二级参考文献33

共引文献8310

同被引文献45

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8234
  • 2董承琅,陶寿淇,陈灏珠.实用心脏病学[M].3版.上海:上海科学技术出版社,1996:1015-1016.
  • 3ITOH M, TSUJI T, NEMOTO K, et al. Undernutrition in patients with COPD and its treatment[J]. Nutrients, 2013, 5(4) : 1316 -1335.
  • 4EKER S, AYAZ L, TAMER L, et al. Leptin, visfatin, insulin re- sistance, and body composition change in chronic obstructive pulmo- nary disease[J]. Scand J Clin Lab Invest, 2010, 70( 1 ) : 40 -44.
  • 5AL SUHAIMI E A, SHEHZAD A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immu- nity[J]. EurJMedRes, 2013, 18: 12.
  • 6MATSUDA A, YANG W L, JACOB A, et al. FK866, a visfatin inhibitor, protects against acute lung injury after intestinal ischemi- a - reperfusion in mice via NF - KB pathway [J]. Ann Surg, 2014, 259(5) : 1007 -1017.
  • 7CIRICZ, STANKOVICI, PEJCICT, et al. Nutrition disorder and systemic inflammation in patients with chronic obstructive pulmona- rydisease[J]. MedGlas (Zeniea), 2013, 10(2):266-271.
  • 8LIU X, JI Y, CHEN J, et al. Circulating visfatin in chronic ob- structive pulmonary disease [ J ]. Nutrition, 2009, 25 (4) : 373 - 378.
  • 9JACQUES C, HOLZENBERGER M, MLADENOVIC Z, et al. Pminflammatory actions of visfatin/nicotinamide phosphoribosyl- transferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity[ J]. J Biol Chem, 2012, 287 (18) : 15100 - 15108.
  • 10LEE W J, WU C S, LIN H, et al. Visfatin - induced expression of inflammatory mediators in human endothelial cells through the NFkappaB pathway[J]. Int J Obes (Lond), 2009, 33(4) : 465 - 472.

引证文献7

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部